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Abstract
Background & Aims: A simultaneous decline in pro- and anticoagulant drivers in pa-
tients with liver diseases results in a “rebalanced” haemostatic system, even in acutely 
ill patients. Nevertheless, both bleeding and thrombotic events are common. Here, we 
explored efficacy of pro- and antihaemostatic strategies in compensated and acutely 
ill cirrhotics which may be unpredictable given the profound haemostatic changes.
Methods: We tested the effects in vitro of the addition of clinically relevant doses of 
commonly used pro- and antihaemostatic strategies in plasma from healthy individu-
als (n = 30) and patients with compensated (n = 18) and acutely decompensated cir-
rhosis (n = 18), and acute- on- chronic liver failure (n = 10). We used thrombin generation 
tests and fibrin clot permeability assays to assess potency of various approaches.
Results: Fresh frozen plasma and recombinant factor VIIa modestly increased throm-
bin generation (10%- 20%). Prothrombin complex concentrate increased thrombin 
generation two- fold in controls and 2- 4- fold in patients. Clot permeability decreased 
after addition of fibrinogen concentrate by 51% in controls and by 50%- 60% in pa-
tients. Low molecular weight heparin decreased thrombin generation by 18% in con-
trols and by 23%- 54% in patients. Similarly, dabigatran decreased thrombin generation 
by 33% in controls and by 47%- 100% in patients. In contrast, rivaroxaban decreased 
thrombin generation by 55% in controls, but only by 11%- 38% in patients.
Conclusions: These in vitro data suggest little prohaemostatic effect of fresh frozen 
plasma and recombinant factor VIIa in acutely ill cirrhotics, whereas prothrombin 
complex concentrate and fibrinogen concentrate clearly improved haemostasis. 
Furthermore, our data suggest the requirement for dose adjustments of commonly 
used anticoagulants in these patients.
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1  | INTRODUC TION
Patients with liver diseases frequently acquire substantial alterations 
in their haemostatic system.1 A simultaneous decline in pro- and an-
ticoagulant drivers results in a “rebalanced” haemostatic system.2-4 
External factors may tip the balance towards hypo- or hypercoagu-
lability,5 and distinct hypo- 6-10 and hypercoagulable11-14 features in 
patients with liver disease which may predispose them to bleeding or 
thrombotic complications.
Bleeding and thrombosis are not uncommon in patients with 
liver disease, in particular in those with advancing and decompen-
sated illness.15 However, little evidence- based treatment strategies 
for prevention or treatment of bleeding or thrombosis are available. 
Current expert recommendations propose a very restrictive prophy-
lactic prohaemostatic management, and a more active anticoagulant 
approach.5,16,17 Importantly, anticoagulant therapy in patients with 
cirrhosis is challenging,18 and new generation anticoagulant drugs 
have not been extensively studied in patients with cirrhosis, al-
though the clinical use in these patients is increasing.19,20
Decompensation may tip the haemostatic balance of patients 
with liver disease towards a bleeding phenotype. A recent study 
has identified thrombocytopenia (with a platelet count <30 000 μL) 
and hypofibrinogenemia (<0.6 g/L) as independent risk factors for 
bleeding in acutely ill patients with cirrhosis.21 It is, however, un-
known whether there is a causal link between bleeding risk and 
these laboratory abnormalities, and studies assessing whether re-
versal of thrombocytopenia and/or hypofibrinogenemia decrease 
the bleeding risk in these patients will be required to ascertain this. 
It is unknown whether acutely ill patients with cirrhosis are at risk 
for development of venous thrombosis similar to the increased 
risk in well compensated patients.22 Nevertheless, prophylactic or 
therapeutic antithrombotic strategies may be required in acutely 
ill patients with cirrhosis, in the context of venous thrombosis, 
portal vein thrombosis, and thrombosis of extracorporeal assist 
devices.15,23
We have recently studied the haemostatic status of patients with 
acutely decompensated or acute- on- chronic liver failure and found 
a remarkably preserved haemostatic system.24 The relatively well- 
preserved haemostatic balance therefore suggests that a defensive 
prohaemostatic and a proactive antihaemostatic approach may be 
warranted in these patients.
Given the major alterations in the haemostatic system of pa-
tients with cirrhosis, the efficacy of pro- and antihaemostatic strat-
egies may be unpredictable. We have previously demonstrated that 
in patients with compensated cirrhosis the in vitro anticoagulant ef-
fects of some of the commonly used drugs was decreased, whereas 
the anticoagulant effects of others were increased as compared to 
anticoagulant effects in healthy individuals.25,26 Another study has 
shown a lack of prohaemostatic effect of in vitro addition of fresh 
frozen plasma to plasma from patients with compensated cirrho-
sis, despite improvements in plasma levels of coagulation factors.27 
Similarly, transfusion of platelets to patients with cirrhosis did in-
crease the platelet count, but did not improve global haemostasis.28
With the aim to provide a more rational approach to pro- and 
antihaemostatic treatment of acutely ill patients with cirrhosis, and 
to facilitate design of future clinical studies, we tested the in vitro 
effects of commonly used pro- and antihaemostatic strategies in 
plasma from patients with acutely decompensated cirrhosis and 
acute- on- chronic liver failure.
2  | MATERIAL S AND METHODS
2.1 | Patients
The study was performed at King’s College Hospital, a 950- bed ter-
tiary hospital in London, United Kingdom, between August 2013 and 
August 2015. The study was approved by NRES Committee London- 
Westminster, Study Number 12/LO/1417. Informed consent or assent 
was obtained from participants or their personal consultees. Details 
on patient recruitment and blood sampling have been published pre-
viously.24 In short, patients were sampled on admission and patients 
were only excluded when currently using antihaemostatic agents. 
From the published cohort we studied 30 healthy volunteers, 18 pa-
tients with acute decompensation (AD) of cirrhosis and 10 patients 
with acute- on- chronic liver failure (ACLF). Eighteen patients with well 
compensated cirrhosis were newly recruited in the outpatient clinic, 
and were not using antihaemostatic drugs at the time of sampling. 
Acute decompensation of chronic liver disease and ACLF were de-
fined and graded according to number of organ failures in concord-
ance with criteria reported in the CANONIC study.29 From the 10 
patients with ACLF, 1 was classified as grade 1 and 9 were grade 3.
2.2 | Routine laboratory tests
Haemoglobin, white blood cell count, albumin, creatinine, bilirubin, 
aspartate transaminase, alanine transaminase and gamma- glutamyl 
Key points
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transpeptidase were measured in the diagnostic laboratory of King’s 
College Hospital for routine clinical care. International normalized 
ratios, and plasma levels of fibrinogen, antithrombin, factor II, fac-
tor VIII and factor X were measured in stored frozen samples on an 
automated coagulation analyzer (ACL 300 TOP) with reagents and 
protocols from the manufacturer (Werfen, Breda, The Netherlands).
2.3 | In vitro addition of pro- and anticoagulants
We added the following agents to plasma samples of each patient 
and control: 
• Recombinant factor VIIa (Novo Nordisk, Bagsvaerd, Denmark)-
final concentration 50 nmol/L
• Cofact (a 4-factor prothrombin complex concentrate (PCC), 
Sanquin, Amsterdam, Netherlands)-final concentration 0.5 U/mL
• Pooled normal plasma (to mimick fresh frozen plasma [FFP] trans-
fusion-obtained by combining plasma from >200 healthy volun-
teers, a generous gift from Dr. J.C. Meijers, Academic Medical 
Center Amsterdam, the Netherlands)-final concentration 20% (v/v)
• Fibrinogen concentrate (CSL Behring, Marburg, Germany)-final 
concentration 1 g/L
• Rivaroxaban, a direct factor Xa inhibtor (Alsachim, Illkirch 
Graffenstaden, France)-final concentration 25 ng/mL
• Dabigatran, a direct thrombin inhibitor (Alsachim, Illkirch 
Graffenstaden, France)-final concentration 300 ng/mL
• The low molecular weight heparin (LMWH) Clexane (Sanofi-
Aventis BV, Gouda, the Netherlands)-final concentration 0.2 U/mL
Plasma levels of procoagulant drugs were chosen to represent clin-
ically relevant (peak) levels observed in clinical use in the general pop-
ulation. The final concentrations of the anticoagulant drugs were also 
chosen to represent clinically relevant plasmas levels and were identi-
cal to levels used in previously published experiments.25 Importantly, 
drug concentrations which gave appreciable (but not maximal) inhibi-
tion of thrombin generation in pooled normal plasma were selected 
so it would be possible to detect both increased and decreased drug 
effects in patients compared to controls.
2.4 | Thrombin generation
The thrombin generation test was performed using platelet- poor 
plasma with the fluorimetric method described by Hemker,30 
Calibrated Automated Thrombography® in absence or presence of 
the above- mentioned agents, except for fibrinogen concentrate. 
Coagulation was activated using commercially available reagents 
containing recombinant tissue factor (final concentration 5 pmol/L), 
phospholipids (final concentration 4 μmol/L), in the presence of 
soluble thrombomodulin (TM, the concentration of which is not 
revealed by the manufacturer). These reagents were purchased 
from Thrombinoscope BV, Maastricht, the Netherlands. Thrombin 
Calibrator (Thrombinoscope BV) was added to calibrate the throm-
bin generation curves. A fluorogenic substrate with CaCl2 (FluCa- kit, 
Thrombinoscope BV, Maastricht, the Netherlands) was dispensed in 
each well to allow a continuous registration of thrombin generation. 
Fluorescence was read in time by a fluorometer, Fluoroskan Ascent® 
(ThermoFisher Scientific, Helsinki, Finland). All procedures were un-
dertaken according to the protocol suggested by Thrombinoscope B.V.
The pro- or anticoagulant potency of the different agents was 
expressed as the percentual change in endogenous thrombin po-
tential (ETP), lag time, peak or velocity index after addition of the 
study agent. These percentages were compared between patients 
and controls.
2.5 | Fibrin concentration and fibrin permeability
Fibrinogen levels in plasma of patients and healthy volunteers 
were determined on an ACL TOP 300 analyzer using reagents from 
Instrumentation Laboratory (Breda, the Netherlands) according to 
the manufacturer’s instructions.
The average pore size of the fibrin clot (expressed as the Darcy 
constant, Ks) was determined in permeation studies as previously 
described.11 In short, plasma samples (100 μL) were incubated with 
10 μL of activation buffer (final concentration of 1 IU/mL thrombin, 
20 mmol/L CaCl2, in tris- buffered saline, pH 7.5) to generate clots. After 
mixing, 100 μL was immediately transferred to a 4.5- cm plastic tip with 
a roughened interior surface, which was cut off from a 1 mL serological 
pipette (Corning Costar Stripette; Sigma- Aldrich, St Louis, MO, USA), 
and left for 2 hours in a moist chamber at room temperature to consol-
idate. The plastic tip was then connected through a flexible silicon tube 
to a syringe containing TBS with a 4- cm pressure drop. After a wash-
out period of 90 minutes with tris- buffered saline, preweighed tubes 
were attached to the clotting tip, and tris- buffered saline drops passing 
through the clot were collected every 30 minutes for 2 hours. The total 
volume of liquid passing through the clot was weighed after collection. 
Permeation of tris- buffered saline through the clot was quantified ac-
cording to the flow rate and the following equation, Ks = (Q × L × η)/T 
× A × P, where Ks = Darcy’s constant, Q = volume of liquid (mL), L = clot 
length (cm), η = viscosity (poise), T = time (s), A = cross- sectional area of 
the clot (cm2), and P = pressure drop (dyne/cm).
2.6 | Statistical analyses
Data are expressed as means (with standard deviations (SDs)), me-
dians (with interquartile ranges), or numbers (with percentages) 
as appropriate. Multiple groups were compared using One- way 
ANOVA (with the Tukey’s post- test) or Kruskal- Wallis H test (with 
Dunn’s post- test) as appropriate. P values of .05 or less were consid-
ered statistically significant. GraphPad Prism (San Diego, USA) and 
GraphPad Instat (San Diego, USA) were used for analyses.
3  | RESULTS
We studied the effects of ex vivo addition of commonly used 
pro- and anticoagulant drugs in patients with compensated and 
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decompensated cirrhosis, and in patients with acute- on- chronic liver 
failure and compared results with those obtained in healthy controls. 
Table 1 summarises baseline characteristics of patients and controls.
Without the addition of pro- or anticoagulant agents, patients 
generated more thrombin as compared to controls, using TM- 
modified thrombin generation tests, which is in line with our previ-
ously published data (Table 2).
When recombinant factor VIIa (50 nmol/L) was added to plasma 
of healthy individuals, an increase of ~20% in ETP, peak, and velocity 
index was observed, with an ~20% decrease in lag time. In patients, 
however, addition of recombinant factor VIIa did not appreciably 
change ETP, peak, and velocity index, whereas the lag time was 
shortened to a similar extent as in controls (Table 3, Figure 1).
Addition of the PCC Cofact (0.5 U/mL) to plasma of healthy 
individuals resulted in an approximate doubling of total thrombin 
generation (to 829 [697- 1141] nmol/L IIa × min). An exaggerated re-
sponse was observed in plasma from patients with a 110% increase 
in the compensated cirrhosis group (to 1525 [1052- 1697] nmol/L IIa 
× min), a 150% increase in thrombin generation in the AD group (to 
1869 [1734- 2210] nmol/L IIa × min) and a 270% increase in the ACLF 
group (to 2383 [1731- 3538] nmol/L IIa × min). Similarly, the peak and 
velocity index increased substantially more in patients compared to 
controls. The lag time did not appreciably change in either controls 
or patients (Table 3, Figure 1).
Addition of pooled normal plasma (20% v/v) increased total 
thrombin generation in controls by 16%, with very similar changes in 
compensated and AD patients (9%- 19% increase). Addition of pooled 
normal plasma to samples of patients with ACLF led to a more pro-
found increase in thrombin generation (38% increase), but given the 
lower baseline thrombin generation levels in the ACLF group, total 
thrombin generation after addition of pooled normal plasma was 
comparable between AD and ACLF patients (913 [841- 980] vs 883 
[757- 993] nmol/L IIa × min) - Table 3, Figure 1.
The permeability of clots generated from plasma from healthy 
controls was remarkably similar to that of the permeability of clots 
from patients, despite the lower fibrinogen levels in patient plasma. 
When fibrinogen concentrate (1 g/L) was added to control samples, 
a 51% reduction in permeability was observed. A similar effect of 
fibrinogen concentrate was observed in patients compensated cir-
rhosis, whereas a slightly more robust effect was observed in plasma 
from AD and ACLF patients with a 61% reduction in permeability in 
the AD group and a 63% reduction in the ACLF group (Table 4).
TABLE  1 Patient characteristics
Controls (n = 30)
Compensated 
(n = 18) AD (n = 18) ACLF (n = 10)
Age 37 ± 7 60 ± 13 54 ± 14 56 ± 10
Gender (male, %) 15 (50%) 12 (67%) 5 (50%) 13 (72%)
CLIF- SOFA n/a n/a 4 ± 2 10 ± 4
MELD n/a 9 ± 2 16 ± 9 31 ± 9
Reason for 
decompensation
n/a n/a Ascites n = 4 
Variceal bleeding n = 4 
Encephalopathy n = 10
Sepsis n = 4 
Variceal bleeding n = 4 
SBP n = 2
Haemoglobin (g/L) n/d 145 (113- 145) 111 (93- 128) 95 (77- 116)
WBC (× 109/L) n/d 5 (4- 6) 6 (3- 9) 10 (8- 19)
Platelets (× 109/L) n/d 119 (87- 150) 95 (65- 132) 89 (65- 111)
Albumin (g/L) n/d 41 (39- 45) 33 (30- 37) 28 (26- 33)
Creatinin (μmol/L) n/d 82 (70- 89) 67 (56- 93) 135 (94- 224)
Bilirubin (μmol/L) n/d 19 (11- 25) 44 (30- 71) 362 (116- 493)
AST (U/L) n/d 42 (37- 45) 47 (38- 56) 79 (50- 86)
ALT (U/L) n/d 36 (24- 43) 25 (18- 30) 46 (24- 61)
GGT (U/L) n/d 60 (33- 143) 77 (47- 135) 37 (30- 91)
INR 1.0 ± 0.1 1.1 ± 0.1 1.6 ± 0.4**,*** 2.1 ± 0.4**,****
Fibrinogen (g/L) 2.8 ± 0.4 3.3 ± 0.7 2.2 ± 0.9*,*** 1.3 ± 0.3**,****
Antithrombin (%) 107 ± 11 88 ± 26* 46 ± 18**,*** 28 ± 14**,****
FII (%) 101 ± 18 78 ± 17** 48 ± 16**,*** 31 ± 10**
FVIII (%) 99 ± 36 157 ± 42** 146 ± 27* 212 ± 93**,****
FX (%) 105 ± 23 85 ± 21* 57 ± 20**,*** 41 ± 15**
ALT, alanine transaminase; AST, aspartate transaminase; CLIF- SOFA, Chronic Liver Failure- Sequential Organ Failure Assessment; F, factor; GGT, 
gamma- glutamyl transpeptidase; INR, international normalised ratio; MELD, model for end- stage liver disease; n/a, not applicable; n/d, not determined; 
SBP, spontaneous bacterial peritonitis; WBC, white blood cell. Shown are means ± standard deviation or medians (interquartile range). *P < .05 vs 
control, **P < .01 vs control, ***P < .01 vs compensated, ****P < .01 vs AD.
1992  |     LISMAN et AL.
Addition of rivaroxaban (25 ng/mL) to plasma from healthy con-
trols resulted in a 55% decrease in the ETP (to 178 [152- 339] nmol/L 
IIa × min), with similar changes in peak and velocity index. The re-
duction in total thrombin generation was less profound in patients, 
particularly in the AD group in which the ETP was only reduced by 
11% (to 629 [527- 692] nmol/L IIa × min) with a 25% reduction in the 
ACLF group (to 465 [367- 570] nmol/L IIa × min), and a 38% reduc-
tion in the compensated group (to 403 [271- 510] nmol/L IIa × min). 
Although the reduction in thrombin generation was substantially 
decreased in patients, the lag time was substantially more prolonged 
in patients compared to controls, particularly in the ACLF group 
(Table 5, Figure 2).
Addition of dabigatran (300 ng/mL) decreased total thrombin 
generation in controls by 33% (to 333 [221- 539] nmol/L IIa × min), 
and prolonged the lag time more than 6- fold. In patients, total throm-
bin generation was decreased by 47% in the compensated group (to 
308 [256- 401] nmol/L IIa × min), by 75% in the AD group (to 171 [63- 
229] nmol/L IIa × min), and none of the patients in the ACLF group 
generated any thrombin in the presence of dabigatran (Table 5, 
Figure 2).
LMWH (0.2 U/mL) decreased the ETP by 18% in controls (to 374 
[291- 471] nmol/L IIa × min), with similar changes in peak and velocity 
index. The decrease in the ETP was more pronounced in patients 
with a 23% decrease in the compensated group (to 526 [425- 632]), 
a 41% decrease in the AD group (to 463 [390- 594] nmol/L IIa × min) 
and a 54% decrease (to 311 [213- 403] nmol/L IIa × min) in the ACLF 
group (Table 5, Figure 2). However, given the higher baseline ETP in 
patients, the ETP in the presence of LMWH were similar between 
patients and controls.
4  | DISCUSSION
Here we have studied the in vitro effects of commonly used pro- and 
anticoagulant strategies in compensated and acutely ill patients with 
cirrhosis in comparison to healthy individuals and found remarkable 
ETP (nmol/L IIa 
× min) Peak (nmol/L IIa) Lag time (min)




122.8 (93.9- 180.3) 1.67 (1.46- 1.98) 61.9 (46.3- 96.5)
CC 699.5 
 (538.5- 819.3)
184.5 (152.0- 211.3) 1.67 (1.33- 1.67) 99.0 (75.8- 111.0)
AD 736.3  
(696.2- 882.3)**




124.5 (86.5- 144.6) 1.92 (1.67- 2.00) 60.3 (43.4- 75.0)
Shown are medians (interquartile ranges). *P < .05, **P < .01 vs controls.
TABLE  2 Thrombin generation 
parameters of thrombomodulin- modified 
thrombin generation testing in controls 
and patients with compensated (CC) or 
acutely decompensated cirrhosis (AD), or 
acute- on- chronic liver failure (ACLF)
ETP Peak Lag time Vel index
rFVIIa
Controls 21 (8- 32) 20 (8- 32) 28 (20- 34) 20 (11- 42)
CC 3 (0- 16)* 2 (−3 to  9)** 21 (20- 30) 1 (−6 to  20)*
AD 2 (−1 to  5)*** −1 (−3 to  3)*** 24 (17- 37) 0 (−10 to  5)***
ACLF 3 (−3 to  27)* −1 (−4 to  19)* 20 (15- 25)* 3 (−6 to  25)
Cofact
Controls 92 (788- 101) 72 (46- 89) 0 (0- 17) 72 (38- 93)
CC 109 (82- 149) 89 (55- 102) 0 (0- 0) 78 (55- 104)
AD 151 (135- 197)*** 109 (87- 150)** 0 (−13- 6) 97 (75- 136)*
ACLF 273 (212- 393)*** 176 (141- 219)*** 10 (0- 17) 178 (156- 265)***
Pooled normal plasma
Controls 16 (2- 21) 15 (−3- 19) 0 (−10- 0) 15 (−4- 19)
CC 7 (−1- 21) 7 (0- 18) 20 (0- 26) 6 (−4- 18)
AD 19 (8- 29) 23 (10- 33) −11 (−25- 0) 22 (12- 31)
ACLF 38 (27- 69) *** 56 (47- 124) *** 0 (−9- 9) 59 (45- 117) ***
Shown are the percentual increase of the ETP, peak, or velocity index, and the percentual decrease 
in the lag time. Data are expressed as median percentages with interquartile range.*P < .05, **P < .01, 
***P < .001 vs controls.
TABLE  3 Percentual changes in 
thrombin generation parameters of 
thrombomodulin- modified thrombin 
generation testing in controls and patients 
with compensated (CC) or acutely 
decompensated cirrhosis (AD), or 
acute- on- chronic liver failure (ACLF) after 
in vitro addition of prohaemostatic agents
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differences in the potency of these strategies between patients and 
controls. Notably, the in vitro efficacy of the procoagulant PCC and 
the anticoagulants dabigatran and LMWH increased with increas-
ing severity of disease, and the efficacy of rivaroxaban was lower 
in patients although not proportional to the severity of disease. The 
increase in efficacy of PCC, dabigatran, and LMWH with increasing 
severity of disease mirror the haemostatic changes that are more 
profound in the sicker patients. The results of this study may have 
clinical relevance as it suggests a requirement for dose- adjustments 
for a number of agents tested, and suggests some agents to be clini-
cally ineffective in these patients. Specifically, the lack of a procoag-
ulant effect of recombinant factor VIIa in patients, and the minimal 
effect of FFP in the AD group are in line with the lack of evidence 
supporting the use of recombinant factor VIIa in patients with liver 
diseases,31-33 and with the doubts on the use of FFP in patients with 
liver disease in general.34 Our data suggest a procoagulant approach 
with PCCs and or fibrinogen concentrate to substantially improve 
haemostatic status in acutely ill patients with liver disease given the 
profound procoagulant effects of PCC in thrombin generation tests 
and the improvement of fibrin clot structure by fibrinogen concen-
trate. This strategy has been reported to be effective in managing 
bleeding during liver transplantation.35 However, based on our data, 
dosing of PCCs should be performed conservatively in acutely ill pa-
tients with cirrhosis given the profoundly exaggerated procoagulant 
response in patients compared to controls. Similarly, our data sug-
gest that substantial dose- adjustments may be required when low 
molecular weight heparin or direct oral anticoagulants are consid-
ered for prophylaxis or treatment of thrombotic complications in 
acutely ill patients with cirrhosis.
The lack of a procoagulant effect of recombinant factor VIIa 
in patients with cirrhosis suggests competent tissue factor- 
mediated activation of coagulation in these patients, and is also 
in line with a very modest increase in thrombin generation follow-
ing administration of recombinant factor VIIa to healthy volun-
teers.36 However, as recombinant factor VIIa also has important 
tissue factor- independent procoagulant activity,37 it cannot be 
presumed that this drug does not have some prohaemostatic ef-
fect in acutely ill patients with cirrhosis in vivo. It has been pre-
viously demonstrated that FFP has no appreciable effects on in 
vitro thrombin generation in plasma from patients with compen-
sated cirrhosis, despite clear changes in plasma levels of coagu-
lation factors and a decrease in the INR.27 Here we demonstrate 
F IGURE  1 Absolute ETP values from 
thrombomodulin- modified thrombin 
generation testing in controls and 
patients with compensated or acutely 
decompensated cirrhosis (AD), or acute- 
on- chronic liver failure (ACLF) prior to and 
after in vitro addition of prohaemostatic 
agents. Indicated are percentual changes 
in the ETP after addition of procoagulant 
agents. Shown are medians with 
interquartile ranges . PNP, pooled normal 
plasma
TABLE  4 Fibrinogen levels and fibrinogen permeability in controls and patients with compensated (CC) or acutely decompensated 
cirrhosis (AD), or acute- on- chronic liver failure (ACLF) in the absence and presence of fibrinogen concentrate
Fibrinogen (g/L) Permeability (Ks)




Controls 2.8 ± 0.4 9.2 × 10−9 ± 3.2 × 10−9 4.2 × 10−9 ± 1.0 × 10−9 51 ± 11
CC 3.3 ± 0.7 9.0 × 10−9 ± 4.0 × 10−9 4.1 × 10−9 ± 2.0 × 10−9 52 ± 11
AD 2.2 ± 0.9* 8.8 × 10−9 ± 3.6 × 10−9 3.7 × 10−9 ± 1.1 × 10−9 61 ± 15 *
ACLF 1.3 ± 0.3** 10.9 × 10−9 ± 5.1 × 10−9 4.0 × 10−9 ± 1.8 × 10−9 63 ± 17*
Data are expressed as means ± standard deviation. *P < .05, **P < .001 vs controls.
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comparable effects of pooled normal plasma (mimicking FFP 
transfusion) in plasma from healthy individuals and patients with 
acutely decompensated cirrhosis, suggesting FFP to be ineffec-
tive in AD patients. The slight increase in thrombin generation in 
our control group is likely clinically insignificant and may reflect 
minor differences in coagulation profiles between our healthy 
individuals (from London, UK) and our pooled normal plasma 
(which was generated in Amsterdam, the Netherlands). Our data 
suggests FFP does have some haemostatic effect in patients with 
ACLF. However, the drawback of FFP administration in these 
acutely ill patients is the risk of volume overload and exacerbation 
of portal hypertension.
TABLE  5 Percentual decrease in thrombin generation parameters of thrombomodulin- modified thrombin generation testing in controls 
and patients with compensated (CC) or acutely decompensated cirrhosis (AD), or acute- on- chronic liver failure (ACLF) after addition of 
anticoagulants
ETP Peak Lag time Vel index
Rivaroxaban
Controls 55 (50- 63) 62 (56- 69) 34 (25- 46) 70 (62- 75)
CC 42 (32- 50)* 53 (44- 57)* 60 (50- 100)*** 60 (44- 68)*
AD 11 (10- 30)*** 19 (18- 35)*** 52 (41- 63)* 33 (27- 47)***
ACLF 25 (11- 35)** 43 (27- 52)** 70 (56- 87)*** 54 (43- 64)*
Dabigatran
Controls 33 (16- 48) 33 (20- 65) 571 (314- 711) 30 (5- 76)
CC 50 (35- 63) 56 (41- 73) 455 (365- 617) 53 (29- 75)
AD 75 (93- 73)*** 92 (84- 98)*** 483 (298- 614) 95 (87- 99)**
ACLF No thrombin formed*** No thrombin formed*** No thrombin formed*** No thrombin formed***
LMWH
Controls 18 (9- 28) 15 (6- 26) 0 (0- 10) 14 (−2- 32)
CC 25 (16- 30) 15 (5- 27) 26 (17- 54) 8 (−4- 20)
AD 41 (26- 48)** 26 (13- 30) 17 (7- 29)** 16 (1- 29)
ACLF 54 (39- 61)*** 29 (24- 42)** 9 (0- 28) 25 (14- 41)
Shown are the percentual decrease of the ETP, peak, or velocity index, and the percentual increase in the lag time. Data are expressed as median per-
centages with interquartile range.*P < .05, **P < .01, ***P < .001 vs controls.
F IGURE  2 Absolute ETP values from 
thrombomodulin- modified thrombin 
generation testing in controls and 
patients with compensated or acutely 
decompensated cirrhosis (AD), or acute- 
on- chronic liver failure (ACLF) prior to 
and following addition of anticoagulant 
agents. Indicated are percentual changes 
in the ETP after addition of anticoagulant 
agents. Shown are medians with 
interquartile ranges
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The substantially increased procoagulant capacity of PCCs in 
plasma from acutely ill patients with cirrhosis likely relates to the 
low baseline plasma levels of procoagulant proteins. The same dose 
of PCC thus results in a much larger relative increase in levels of 
the vitamin K- dependent factors in patients compared to controls. 
Baseline thrombin generating capacity is elevated in patients com-
pared to controls, despite the much lower levels of procoagulants, 
as the levels of anticoagulant proteins are also low. Therefore, the 
procoagulant effects of PCCs are much more prominent in patients 
compared to controls. The preserved fibrin clot structure in pa-
tients is in line with our previous results showing preserved fibrin 
clot structure in patients with compensated cirrhosis to be related 
to oxidative modifications to the fibrinogen molecule.11 Fibrinogen 
concentrate profoundly decreases fibrin clot permeability in acutely 
ill patients with cirrhosis, which is in line with our previous study 
showing that fibrinogen concentrate normalizes fibrin clot permea-
bility in samples taken from patients during liver transplantation.38
The increased anticoagulant potency of LMWH and pro-
foundly increased anticoagulant potency of dabigatran are in line 
with previous studies in patients with compensated cirrhosis,25,39 
and suggest a requirement for conservative dosing particularly 
of dabigatran in acutely ill patients with cirrhosis. Importantly, 
although it remains to be established whether dose- adjustments 
and/or monitoring of drug levels improves the anticoagulant 
management of acutely ill patients with cirrhosis, monitoring of 
LMWH by anti- Xa testing is unreliable in patients with cirrhosis.40 
Thrombin generation tests are currently not ready for clinical use, 
but the development of whole blood generation tests may result 
in a point- of- care thrombin generation test which may be suitable 
for anticoagulant monitoring,41 which might be used to monitor 
anticoagulant treatment in these difficult patients. Rivaroxaban 
appears less effective in patients compared to controls which is 
in line with studies in patients with compensated cirrhosis,25 and 
dose increases may be required. However, importantly, although 
rivaroxaban is less effective in patients as assessed by total throm-
bin generation, it appears more effective compared to controls in 
prolonging the lag time of thrombin generation which was also ob-
served in our previous study in compensated cirrhosis.25
Taken together, our results suggest a profound difference in 
clinical efficacy of some of the commonly used pro- and antico-
agulant strategies in compensated and acutely ill patients with 
cirrhosis. Dose adjustments of some of these agents may be re-
quired, either to improve efficacy or to decrease the risk of side 
effects. Although our studies have been performed using in vitro, 
plasma- based systems, which do not take the role of blood cells 
in haemostasis into account, these results may still be clinically 
relevant. We propose that our study is the starting point for future 
preclinical and clinical studies that will further explore the need 
for alternative dosing of pro- and anticoagulants in patients with 
cirrhosis. Our data may assist in development of urgently needed 
clinical studies to assess safety and efficacy of strategies to pre-
vent or treat bleeding and thrombotic complications in these com-
plex patients.
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